RxDoctor Payments Data

Astrid Alvarez

Physician Assistant · Redlands, CANPI 1699371773

Payments from drug & device makers

$2,032in general payments, 2019–2025

Across 85 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$432
  • AbbVie$398
  • Teva Pharmaceuticals USA, Inc.$181
  • Lilly USA, LLC$174
  • Novartis$165
  • Biohaven Pharmaceutical Holding Company Ltd.$127
  • plus $556 from 14 others

What the payments were for

  • Food & beverage$2,032100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,032 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$7,188
Medicare patients
83
Services billed
281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$103,773
RybelsusSemaglutide29$37,964
JanuviaSitagliptin Phosphate35$34,711
EliquisApixaban23$17,509
FarxigaDapagliflozin Propanediol11$15,364
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$12,445
MyrbetriqMirabegron11$4,706
Albuterol Sulfate HfaAlbuterol Sulfate84$2,538
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,121
Atorvastatin Calcium224$1,657
Gabapentin99$1,492
Levothyroxine Sodium140$1,476
Diclofenac Sodium86$1,328
Rosuvastatin Calcium50$919
Ondansetron Hcl14$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$432$141,737127 claims
MerckJanuvia$17$34,71135 claims
PfizerEliquis$70$17,50923 claims
Astellas Pharma US IncMyrbetriq$80$4,70611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →